RT Journal
A1 LOVE V
T1 EFfect of thyroxine analogue tfa-4 on serum cholesterol
JF Archives of Internal Medicine
JO Archives of Internal Medicine
YR 1961
FD December 1
VO 108
IS 6
SP 833
OP 836
DO 10.1001/archinte.1961.03620120017003
UL http://dx.doi.org/10.1001/archinte.1961.03620120017003
AB The role of thyroxine in the control of serum cholesterol has long been recognized clinically. In hypothyroidism hypercholesteremia assumes some diagnostic importance; whereas, a tendency to hypocholesteremia is often recorded in hyperthyroidism. The administration of desiccated thyroid and thyroid extracts will reduce the serum cholesterol and phospholipid.1At the present time a rather voluminous literature points to the probability that elevated lipids constitute one of the factors involved in atherogenesis. Therefore, if thyroxine could be altered so as to maintain its cholesterol-lowering effect without altering general body metabolism a useful research and possible therapeutic tool would be available. It is the purpose of this paper to present a clinical experience with one of these thyroxine analogues.Tetraiodothyroformic acid (TFA-4) is formulated by substituting a carboxyl group for the alanine side-chain of thyroxine (Fig. 1). Duncan and Best2-4 studied this compound in rats and found that, when compared to